

LIST OF TABLES

Table No.	TITLE	Page No.
2.1.	Demographic details of the bancroftian patients	40
2.2	Demographic details of the brugian patients	40
2.3	Demographic details of the MF patients used for DEC follow up studies.	41
2.4.	Primers used for PCR amplification of pRBSXP filarial gene	48
2.5.	pRBSXP gene size and expected protein molecular weight	49
3.1	Quantitation of circulating filarial antigen (CFA) by Og4C3 assay in different clinical groups of bancroftian filariasis	60
3.2	Quantitation of circulating filarial antigen (CFA) by Og4C3 assay in different clinical groups of bancroftian filariasis	63
3.3	Recovery of purified pRBSXP antigen from IMAC column using different elution technique	78
3.4	Detection of circulating filarial antigen (Og4C3) and pRBSXP specific IgG4 antibody levels from blood collected on filter strips from bancroftian MF patients	83
3.5	Comparison of pRBSXP specific IgG4 assay with the existing IgG4 assay using different crude filarial antigens in brugian filariasis	85
3.6	Mean \pm SEM Og4C3 antigen levels and pRBSXP specific IgG4 levels in bancroftian MF patients from two different endemic areas.	91
3.7	pRBSXP antigen levels in different clinical groups of Bancroftian filariasis	106
3.8	Comparison of circulating pRBSXP and Og4C3 antigen assay in different clinical group of bancroftian filariasis	106
3.9	pRBSXP antigen levels in different clinical groups of Brugian filariasis	109
3.10	Comparison of pRBSXP specific antigen assay with Og4C3 assay in different clinical group of brugian filariasis	109